ArticleJournal of the National Cancer Institute2025
Prostate-specific antigen levels at age 60 years and lifetime risk of lethal prostate cancer.
Article in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Trial
- Cancer statistics, 2026.CA: a cancer journal for cliniciansArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundWe investigated the natural history of the relationship between prostate-specific antigen (PSA) at age 60 years and lifetime risk of prostate cancer death in an unscreened cohort followed for 40 years in the Malmö Preventive Project. We also investigated whether percent-free PSA could risk-stratify men with low PSAs.
methodsThe cohort included 1162 men aged 58-62 years at blood draw in 1981-1982, with 1151 deaths by December 31, 2020. Total and free PSA were measured for 130 men with prostate cancer and 517 without prostate cancer. Lorenz curves were calculated for life years lost to prostate cancer by baseline PSA level.
resultsTotal PSA at age 60 years remained highly predictive for full lifetime risk of lethal prostate cancer (C index = 0.87, 95% confidence interval [CI] = 0.82 to 0.92). More than half of the life years lost to prostate cancer in this cohort were in men who had a PSA above 4.0 ng/ml (59%, 95% CI = 54% to 63%) at age 60 years, with 85% (95% CI = 81% to 89%) and 92% (95% CI = 90% to 94%) in men with a PSA above 2.0 ng/ml and above 1.0 ng/ml, respectively. Percent-free PSA did not aid risk stratification in men with low PSA.
conclusionsMen with a PSA below 1-2 ng/ml at age 60 years are at low risk for lethal prostate cancer and do not require further PSA screening. Unlike a proven role in men with elevated PSA, percent-free PSA is not useful in informing the decision to stop or continue further PSA screening for men with a PSA below 2 ng/ml at age 60 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.